Small Molecule Drugs for Obesity: A Scalable, Oral Alternative to Peptide-Based Therapies
Obesity remains one of the most pressing public health crises of the current time. Beyond the difficulty of achieving weight loss, long-term weight maintenance remains a major hurdle - data shows that up to 80% of lost weight is regained within five years
August 22, 2025
by Neeta Ratanghayra
Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified?
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
March 14, 2025
by Krebs Qin
Breakthrough in Research of Small Molecule Drugs against SARS-CoV-2
Corona virus disease 2019 (COVID-19) caused by a novel single-stranded RNA coronavirus has swept the world. The International Committee on Taxonomy of Viruses (ICTV) named the virus SARS-CoV-2.
March 21, 2022
by PharmaSources/Xiaonisha
Roche, Jnana sign multi-target collaboration deal for small molecule drugs
Jnana Therapeutics has signed a multi-target collaboration and license deal worth over $1bn with Roche for the discovery of small molecule drugs for the treatment of immune-mediated and neurological diseases.
July 24, 2020
by pharmaceutical-business-review
Biologics or small molecule drugs for rare disease treatment? It is a question
To both patients and pharmaceutical practitioners, it is a question as to whether to choose biologics or small molecule drugs for rare disease treatment, since the prices are sky-high.
July 31, 2019
by PharmaSources/Miling
Skyhawk and Takeda partner to develop small molecule drugs
US-based Skyhawk Therapeutics has formed a strategic alliance with Takeda Pharmaceutical to discover and develop small molecule drug candidates for multiple targets across neurodegenerative diseases.
May 8, 2019
by pharmaceutical-technology
RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D
RedHill Biopharma Ltd. announced that the last patient enrolled in the Phase II study with BEKINDA® (RHB-102)(1) 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) has completed the treatment course and follow-up visit.
July 18, 2017
by b3cnewswire